Literature DB >> 26374214

Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.

Matthias Renner1, Brigitte Anliker2, Ralf Sanzenbacher3, Silke Schuele4.   

Abstract

In the European Union, clinical trials for Advanced Therapy Medicinal Products are regulated at the national level, in contrast to the situation for a Marketing Authorisation Application, in which a centralised procedure is foreseen for these medicinal products. Although based on a common understanding regarding the regulatory requirement to be fulfilled before conduct of a clinical trial with an Advanced Therapy Investigational Medicinal Product, the procedures and partly the scientific requirements for approval of a clinical trial application differ between the European Union Member States. This chapter will thus give an overview about the path to be followed for a clinical trial application and the subsequent approval process for an Advanced Therapy Investigational Medicinal Product in Germany and will describe the role of the stakeholders that are involved. In addition, important aspects of manufacturing, quality control and non-clinical testing of Advanced Therapy Medicinal Products in the clinical development phase are discussed. Finally, current and future approaches for harmonisation of clinical trial authorisation between European Union Member States are summarised.

Keywords:  ATMP; CBMP; Clinical trials; GTMP; Regulatory

Mesh:

Year:  2015        PMID: 26374214     DOI: 10.1007/978-3-319-18618-4_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.

Authors:  Margaux Damerval; Christine Fagnoni-Legat; Aurélien Louvrier; Sarah Fischer; Samuel Limat; Anne-Laure Clairet; Virginie Nerich; Isabelle Madelaine; Marie Kroemer
Journal:  Front Med (Lausanne)       Date:  2021-12-01

Review 2.  Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts.

Authors:  Jessica Hartmann; Martina Schüßler-Lenz; Attilio Bondanza; Christian J Buchholz
Journal:  EMBO Mol Med       Date:  2017-09       Impact factor: 12.137

Review 3.  Accelerating Patients' Access to Advanced Therapies in the EU.

Authors:  Ahmed Elsanhoury; Ralf Sanzenbacher; Petra Reinke; Mohamed Abou-El-Enein
Journal:  Mol Ther Methods Clin Dev       Date:  2017-09-22       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.